The Global Biotech Report 2006 - The rise of the Biotech blockbusters

In stark contrast to the rest of the pharmaceutical industry, the world market for biotech drugs is thriving. In 2005, biotech revenues reached $60bn and visiongain predicts that this will continue - YOU MUST BE PART OF THIS SUCCESS NOW. Order a copy of visiongain’s new report to get the details.

Having grown 16.5 per cent from 2004's revenues, double-digit growth of the market will continue to the end of the decade. You need to be aware of how you can succeed in this area. 1 report will tell you all you need to know.

- Over 250+ pages

- Over 150 tables and figures

- Global revenues & growth rates for the leading biotech drugs

- Company profiles of the leading biotech firms

- A comprehensive analysis of the global market, 2005-2011

- Revenue forecasts for the leading biotech drugs

- Revenues into therapeutic area

- Pipeline treatments

- A geographic breakdown of the market

- A Focus on biogenerics

Designed as an essential business aid, The Global Biotech Report 2006 provides the leading thorough evaluation of your market.

The report provides you with in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena. This is the industry's premier report. Numbers are strictly limited, so order today.

Five key questions this report answer's are:

1. What are the market values of the major therapeutic areas of the global biopharmaceutical market by product from, 2005 to 2011?

2. Who are the major companies involved in the world market today and in the future, and will they be competition to you?

3. How imminent are biogenerics and what is their potential market value?

4. What strategies can be used to maximise your profits in terms of the major challenges facing biotech?

5. What's in the 2006 biopharmaceutical pipeline and what revenues can they reach by 2011?

This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' of your competitors. You can not afford to be without this report from visiongain.

Lead Analyst: Dr Tom Newton Publication Date: 15/09/06 Pages: 250

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.
Table of Contents

Price
Single User Licence $9998.00
Department Licence 5 Users $21998.00
Company-wide Intranet Licence $41998.00